February 03 at 8:03 am
Mesoblast Limited Resubmits Biologics License Application to FDA; New Data Shows Long-Term Survival Outcomes
Mesoblast Limited, (Nasdaq: MESO; ASX:), a global leader in allogeneic cellular medicines for inflammatory diseases has resubmitted its Biologics License Application (BLA) for approval of… [Read More]